Vis enkel innførsel

dc.contributor.authorKristensen, Are Korsnes
dc.contributor.authorSolheim, Tora Skeidsvoll
dc.contributor.authorAmundsen, Tore
dc.contributor.authorHjelde, Harald Harris
dc.contributor.authorKaasa, Stein
dc.contributor.authorSørhaug, Sveinung
dc.contributor.authorGrønberg, Bjørn Henning
dc.date.accessioned2017-08-17T08:25:09Z
dc.date.available2017-08-17T08:25:09Z
dc.date.created2017-07-07T10:07:56Z
dc.date.issued2017
dc.identifier.citationActa Oncologica. 2017, 56 (5), 737-745.nb_NO
dc.identifier.issn0284-186X
dc.identifier.urihttp://hdl.handle.net/11250/2450979
dc.description.abstractBackground: Side effects of chemotherapy may occur at different time-points in the treatment cycle, and the exact assessment time relative to chemotherapy may affect HRQoL scores. The current study examined the variation of HRQoL during chemotherapy cycles, and whether differences in HRQoL scores varied at selected time-points between patients allocated to two different chemotherapy regimens. Material and methods: Patients with stage IIIB or IV non-small-cell lung cancer (NSCLC) were randomly assigned to receive three cycles of carboplatin plus vinorelbine (VC) or gemcitabine (GC) every 3 weeks. HRQoL was reported on the EORTC QLQ-C30 and LC13 on days 1, 4, 8, 11 and 15 of every cycle. Global health status, nausea/vomiting, fatigue and dyspnea (LC13) were defined as the HRQoL scales of primary interest. Results: Fifty-two patients were enrolled. Variation of mean scores of global health status, nausea/vomiting and fatigue showed a consistent pattern during chemotherapy. Day 4 appeared to be the time-point when chemotherapy influenced HRQoL the most. The differences in mean HRQoL scores between the two treatment arms varied at the different time-points, especially for nausea/vomiting. Conclusion: There was a clinically relevant variation of HRQoL during chemotherapy cycles, with increased symptom burden the first week following treatment. Our results suggest that timing of HRQoL assessment can influence the chances of detecting differences between the treatment regimens.nb_NO
dc.language.isoengnb_NO
dc.publisherTaylor & Francisnb_NO
dc.titleMeasurement of health-related quality of life during chemotherapy -the importance of timingnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber737-745nb_NO
dc.source.volume56nb_NO
dc.source.journalActa Oncologicanb_NO
dc.source.issue5nb_NO
dc.identifier.doi10.1080/0284186X.2017.1279748
dc.identifier.cristin1481389
dc.description.localcodeThis is an Accepted Manuscript of an article published by Taylor & Francis in Acta Oncologica on 24 Jan 2017, available online: http://www.tandfonline.com/doi/full/10.1080/0284186X.2017.1279748 . Locked until 24 January 2018 due to copyright restrictions.nb_NO
cristin.unitcode194,65,25,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameInstitutt for kreftforskning og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel